ArticleESMO open2025

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.

A Minchom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.